History of prior immunotherapy within the last 3 yearsH. Major surgery within 4 weeks prior to enrollment (Day 1 visit).I. History of allergic reac tions attributed to compounds of similar chemical or biologic composition to enzalutamide or poxviral vaccines (e.g., vaccinia vaccine) J. Known allergy to eggs, egg product s, aminoglycoside antibiotics (for example, gentamicin or tobramycin). K. History of atopic dermatitis or ac tive skin condition (acute, chronic, exfoliative) that disrupts the epidermis L. Previous serious adverse reactions to smallpox vaccinationM. Unable to avoid close contact or household contact with the following high- ULVNLQGLYLGXDOVIRUWKUHHZHHN VDIWHUWKH'D\YDFFLQDWLRQ  D FKLOGUHQ years of age, (b) pregnant or nursing women, (c) individuals with prior or concurrent extensive eczema or other eczemoid skin disorders, or (d) immunocompromised individuals, such as those with HIV. N. Receipt of an investigational agent within 30 days (or 60 days for an antibody- based therapy) before the first planned dose of study drugs. O.